FDA 483 - Wells Pharma of Houston LLC - December 14, 2022

During an inspection conducted from November 16 to December 14, 2022, the FDA issued a Form 483 to Wells Pharma of Houston LLC, an outsourcing facility. This document, issued under the Federal Food, Drug and Cosmetic Act, highlighted significant observations concerning the firm's operational and quality control practices. Major violations included the inadequate validation of the electronic building monitoring system, which controls critical environmental parameters like differential pressure, temperature, and humidity in classified manufacturing areas. The initial validation was found to lack essential data, and a necessary re-validation was substantially delayed, yet sterile products continued to be released. Additionally, inspectors noted a structural deficiency within the cleanroom environment: a 0.5-inch gap at the base of equipment in an ISO 8 area. This gap created a potential pathway for lower quality air to compromise higher quality processing zones, risking contamination of sterile drug products. The firm's quality control unit also lacked adequate written procedures, specifically failing to define essential differential pressure specifications, alert, and action limits for various classified cleanroom environments. Wells Pharma of Houston LLC is expected to promptly implement robust corrective and preventive actions to address these deficiencies and ensure full compliance with regulatory requirements for drug manufacturing.